Fig. 4

Anti-tumor efficacy of NLG919@DEAP-^DPPA-1. A Schematic representation of the self-assembly process of NLG919@DEAP-^DPPA-1 and its mechanism of action. B, C Percentage of CD8⁺T and IFN-γ-producing cytotoxic T cells in tumors after different treatment regimens. D Survival rate of B16-F10 tumor-bearing mice after different treatment regimens. (Treatment groups: 1: DEAP-^DPPA -1-Scr; 2: NLG919; 3: NLG919@DEAP-^DPPA-1-Scr; 4: DEAP-^DPPA-1; 5: NLG919@DEAP-^DPPA-1, *p < 0.05, **p < 0.01, ***p < 0.001). Reprinted with permission from Ref. [143].